Merck vs Pfizer MRK vs PFE
Merck and Pfizer on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Trailing P/E: Merck 112.5×, Pfizer 39.3×.
- One-year price return: Merck +60.7%, Pfizer +20.3%.
- Operating margin: Pfizer 25.1%, Merck 11.8%.
- Market value: Merck $346.91B, Pfizer $169.79B.
Price return
2025-10-26 → 2026-10-26
MRK+60.7%
PFE+20.3%
Profile
latestSector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
Market value
$346.91B
$169.79B
Enterprise value
$393.97B
$232.01B
Employees
74,000
75,000
Revenue per employee (TTM)
$897K
$849K
Our models
nightlythe valuation on each stock's pagePrice vs model
24% undervalued vs model
39% undervalued vs model
Model range
$106–474
$24.96–113
Models in the headline
1
1
FCF growth priced in, at a 10% return
17.6%
13.3%
Every model, its assumptions and its range: MRK valuation · PFE valuation. The growth priced in, at any return: MRK reverse DCF · PFE reverse DCF.
Trading
close 2026-10-26Last close
$140.61
$29.79
52-week high
$156.45
$30.42
52-week low
$82.49
$23.67
Price vs 52-week high
−10.1%
−2.1%
Price vs 52-week low
+70.5%
+25.9%
Average daily volume / shares
0.4%
0.7%
Beta
0.22
0.28
Returns
to 2026-10-261 month
−5.5%
+3.9%
3 months
+7.3%
+21.4%
6 months
+25.7%
+10.3%
Year to date
+33.6%
+19.6%
1 year
+60.7%
+20.3%
1 year, dividends added
+64.6%
+27.3%
2 years
+35.2%
+4.7%
Valuation
price × TTM to Jun 2026P/E (TTM)
112.5×
39.3×
P/E on consensus EPS (next FY)
53.0×
10.1×
Price / sales
5.2×
2.7×
EV / sales
5.9×
3.6×
EV / EBITDA
28.3×
17.2×
Price / book
8.3×
2.0×
Price / free cash flow (FY)
28.1×
18.7×
Free-cash-flow yield (FY)
3.6%
5.3%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+3.3%
−0.5%
Revenue, 3-year CAGR
3.1%
−14.6%
Revenue, 5-year CAGR
9.4%
8.5%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
−63.6%
+117.3%
EPS, 3-year CAGR
8.4%
−37.1%
Free cash flow, 3-year CAGR
−5.6%
−29.6%
Diluted shares, 3-year change
−1.4%
−0.8%
Profitability
TTM to Jun 2026Gross margin (FY)†
72.0%
70.3%
Operating margin
11.8%
25.1%
EBITDA margin
21.0%
21.2%
Net margin
4.8%
6.8%
Free-cash-flow margin (FY)
19.0%
14.5%
Return on equity
7.6%
5.1%
Return on assets
2.4%
2.2%
Asset turnover
0.51
0.32
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
MRQ Jun 2026Cash
$6.85B
$976.0M
Total debt
$53.91B
$63.19B
Net debt
$47.06B
$62.22B
Debt / equity
1.3×
0.7×
Net debt / EBITDA (TTM)
3.4×
4.6×
Interest coverage (FY)
17.3×
5.8×
Current ratio (FY)
1.54
1.16
Dividends
trailing 12 monthsDividend yield
2.4%
5.8%
Dividends per share
$3.40
$1.72
Payout ratio (of TTM EPS)
272.0%
227.2%
Dividend per share, 5-year CAGR
6.0%
2.1%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
11
11
Insider open-market buys (Form 4)
$0
$3.0M
Insider sales (Form 4)
$30.0M
$83K
Analyst upgrades
2
0
Analyst downgrades
1
0
Statements
income TTM to Jun 2026 · cash flow FY2025Revenue
$66.40B
$63.70B
EBITDA
$13.93B
$13.49B
Operating income
$7.85B
$15.98B
Net income
$3.17B
$4.33B
EPS (diluted)
$1.25
$0.76
Operating cash flow
$16.47B
$11.71B
Capital expenditure
−$4.11B
−$2.63B
Free cash flow
$12.36B
$9.08B
Dividends paid
$8.18B
$9.77B
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.